AN2 Therapeutics Inc (ANTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $172.64M
Last updated: Nov 17, 2026 at 11:04 AM ET
AN2 Therapeutics Inc (ANTX) Stock Forecast
Analysts expect AN2 Therapeutics (ANTX) to earn -$0.81 per share in the fiscal year ending Dec 31, 2026. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.77.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.81
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.77
- EPS consensus
- Next report
- Mar 15, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.81 | -$0.81 to -$0.81 | 1 |
| Dec 31, 2027 | -$0.77 | -$0.80 to -$0.73 | 2 |
Quarterly Estimates
The EPS consensus rises from -$0.24 for the quarter ending Dec 31, 2026 to -$0.19 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.24 | -$0.25 to -$0.22 | 4 |
| Mar 31, 2027 | -$0.19 | -$0.19 to -$0.19 | 1 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.93.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.81 | -$0.90 | -$0.90 | -$0.90 | -$0.93 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.77 | -$0.80 | -$0.80 | -$0.80 | -$0.89 | N/A |
| Quarter ending Mar 31, 2027 | -$0.19 | -$0.21 | -$0.21 | -$0.21 | N/A | N/A |
Frequently Asked Questions About ANTX
What is the ANTX stock forecast?
Consensus analyst estimates put AN2 Therapeutics's EPS at -$0.81 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from ANTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.81, with estimates from -$0.81 to -$0.81 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.77, with estimates from -$0.80 to -$0.73 from 2 analysts.
How many analysts cover ANTX?
1 analyst estimates EPS for AN2 Therapeutics for the fiscal year ending Dec 31, 2026.
ANTX pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts